Page 16 - Lupin

Lupin gets USFDA nod for hypertension treatment drug in US

Drug major Lupin has received tentative approval from the US health regulator to sell Olmesartan medoximil tablets, used for treating high blood pressure, in the American market. "It has received final approval for Olmesartan medoximil tablets, 5 mg, 20 mg and 40 mg from the US Food and Drug Administration (USFDA)," Lupin Ltd said in a BSE filing today. Olmesartan medoximil tablets, generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other antihypertensive agents to lower blood pressure, it added. Quoting IMS MAT September 2016 sales data, Lupin further said that Benicar tablets had annual US sales of USD 1.06 billion. Shares of the company were trading 0.71 per cent up at Rs 1,457 apiece on BSE.

Lupin to launch sleep disorder drug in US

US business contributes over 40 per cent to the company revenue

Lupin gains on tentative approval for generic Epzicom tablets

The stock was up 3.5% at Rs 1,463 on NSE as compared to 0.02% rise in Nifty50 index

Drug major Lupin gets USFDA nod for generic pain relieving medicine

Lupin's shares were trading at Rs 1,425 apiece on the BSE, up 1.24 per cent from their previous close

Lupin's net profits up 57.8% to Rs 662.2 crore

Lupin's India formulation sales grew by 12.1% to Rs 995.8 cr during Q2 FY2017 as compared to Rs 888.1 cr during Q2 FY2016

Lupin Q2 net up 58% at Rs 662 cr

Consolidated total income jumps 29% to Rs 4,290 cr

US clearance of Goa unit a sales boost for Lupin

With inspection issues out of the way, product nods will gather pace, leading to diversification of revenue stream

Lupin surges on receiving EIR report from USFDA for Goa plant

The stock was up 6% at Rs 1,509 on BSE, as compared to 0.8% rise in the S&P BSE Sensex att 09:26 am.

Lupin, MonoSol Rx sign licensing pact for pediatric products

Lupin Pharmaceutical to develop multiple pediatric products utilising MonoSol Rx's proprietary PharmFilm drug delivery technology

Lupin gets USFDA nod for generic drug treating Alzheimer's

Lupin will manufacture a generic version of Allergan's Namenda XR capsules that are used to treat dementia

Lupin, Torrent zero in on Bayer's biz

Dermatology segment of Bayer's portfolio is valued at $1 bn

Lupin caught in legal tussle over 'patent infringement'

Horizon decided to take legal action after Lupin filed an abbreviated new drug application (Anda) for a generic version of Pennsaid

Lupin gets USFDA tentative nod for anti-bacterial tablets

Approval is to market the company's product, a generic version of Bayer Healthcare Pharmaceuticals' Avelox tablets in the same strength

Lupin gets tentative USFDA nod for generic anti-depressant

Company's shares were trading at Rs 1,524.70, up 0.14% in the afternoon trade on BSE

Lupin arm gets USFDA nod to market generic Zyvox tablets

According to IMS MAT June sales data, Zyvox tablets had US sales of $273.6 million

Lupin gets CDSCO nod for indigestion treatment tablets

Acotiamide is approved for the treatment of post meal fullness, bloating and early satiety in functional dyspepsia by the CDSCO

Lupin gets USFDA nod for generic potassium deficiency drug

Company's subsidiary Gavis Pharmaceuticals has received final approval from USFDA to market potassium chloride extended release capsules

Lupin looks to launch 25 products in US this fiscal

Company expects to go ahead with launches on the dermatology front this year

Lupin Pharmaceuticals: Strong show fails to impress

Lukewarm domestic sales partly offset robust growth in US business; Ebitda short of estimates

Lupin Q1 profit up 55% on the back of overseas business

Net income from operations jumped 40% to Rs 4,439 cr